

*Electronic Supplementary Information for*

***Two-step lighting DNA tetrahedral nanoprobe for precise imaging-guided photodynamic therapy of tumor***

Fan Wu<sup>a</sup>, Yuancheng Li<sup>b</sup>, Lijuan Wang<sup>b</sup>, Can Peng<sup>a</sup>, Youhui Zeng<sup>a</sup>, Jinfeng Yang<sup>b,\*</sup>, Junhui Zhou<sup>b,\*</sup>,  
Jing Zheng<sup>a,\*</sup>

<sup>a</sup>State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, China.

<sup>b</sup>Department of Gastroenterology and Urology, Department of Anesthesiology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, China.

\*To whom correspondence should be addressed. Fax/Tel: +86-731-88822523;

E-mail: yangjinfeng@hnca.org.cn; [zhouhuijun@hnca.org.cn](mailto:zhouhuijun@hnca.org.cn); zhengjing2013@hnu.edu.cn;

## Table of Contents

1. Experimental Section.....	S3
1.1 Materials and Instruments.....	S3
1.2 Assembly of the Tetrahedral DNA Nanostructures.....	S3
1.3 Preparation of TAH and TAH@TMPyP4.....	S3
1.4 Gel Electrophoresis Analysis.....	S3
1.5 Responsiveness of Constructed Nanoprobes to MUC1 and Azoreductase in Buffer Solution .	S4
1.6 $^1\text{O}_2$ Production of TAH@TMPyP4 in Buffer Solution.....	S4
1.7 Probe Stability Investigation.....	S4
1.8 Confocal Fluorescence Imaging of TAH in Living Cells.....	S5
1.9 Cytotoxicity Investigation .....	S5
1.10 <i>In Vivo</i> Fluorescence Imaging .....	S6
1.11 <i>In Vivo</i> Photodynamic Therapy Research.....	S6
2. Experimental Data .....	S7

## 1. Experimental Section

### 1.1 Materials and Instruments.

All oligonucleotides were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China) (Table S1) and purified by high-performance liquid chromatography (HPLC). Ultrapure water obtained from a Millipore water purification system (18.2 M $\Omega$ ) used in all assays. 5,10,15,20-Tetrakis-(N-methyl-4-pyridyl) porphine (TMPyP4) was purchased from Sigma-Aldrich (MO, USA). Nicotinamide adenine dinucleotide phosphate (NADPH) was purchased from Beyotime Institute of biotechnology (China), while rat liver microsomes were purchased from CHI Scientific, Inc. (China).

### 1.2 Assembly of the Tetrahedral DNA Nanostructures

Four single-stranded DNAs (S1-S4) were assembled in PBS buffer (20 mM PBS, 10 mM MgCl<sub>2</sub>, 100 mM KCl (pH=7.4) at the same molar ratio) and placed at 95°C for 5 min, then quickly cooled to 4°C in ice, and keep at 4°C for at least 2 h for further use. The final concentration of DNA tetrahedral nanostructures was 1  $\mu$ M.

### 1.3 Preparation of TAH and TAH@TMPyP4

L1, L2 and Apt strands were modified onto the assembled DNA tetrahedra in buffer (20 mM PBS, 10 mM MgCl<sub>2</sub>, 100 mM KCl. pH = 7.4) at appropriate molar ratios (DNA tetrahedra: L1: L2: Apt = 1: 1: 1: 1), and place at 25°C for more than 3 h to prepare TAH. The prepared TAH nanoprobe was stored at 4°C in the dark until use. The TAH@TMPyP4 was prepared by successively adding the TAH to TMPyP4 in the PBS buffer. The mixture was shaken at room temperature for 6 h, and the unloaded TMPyP4 was removed by ultrafiltration for three times. According to the standard curve, we obtained the load amount of TMPyP4 in TAH@TMPyP4.

### 1.4 Gel Electrophoresis Analysis

1.5% agarose gel electrophoresis was used to verify the assembly of DNA tetrahedral nanostructures and TAH nanoprobe. The agarose gel was carried out in

1×TBE buffer at room temperature. The electrophoresis was performed at 100 V for 45 min after loading 10  $\mu$ L samples (1  $\mu$ M) into each lane. The gel was stained with SYBR Gold and scanned *via* Bio-Rad gel imaging system.

### 1.5 Responsiveness of Constructed Nanoprobes to MUC1 and Azoreductase in Buffer Solution

The prepared TAH nanoprobes were added to PBS buffer solutions containing different concentrations of MUC1 (0-200 nM), and the mixed solutions were incubated at room temperature for 1 h. The fluorescence intensity of Cy5.5 was recorded at the excitation wavelength of 673 nm. For the selectivity, different proteins: MUC1 (active or inactive, 100 nM), GOX (100  $\mu$ M), RNase H (1 U/mL), RNase A (10 ng/ $\mu$ L), APE1 (1 U/mL) were added to the reaction buffer TAH (100 nM) for 1 h at 37°C. The fluorescence emission intensity of each sample was measured.

The prepared TAH nanoprobes were incubated with different concentrations (0, 25, 50, 100, 125, 150, 175, 200  $\mu$ g/mL) of rat liver microsomes and 50  $\mu$ M NADPH at 37°C for 6 h under hypoxic conditions (1% O<sub>2</sub>). The fluorescence intensity of TAMRA was recorded every 1 h using the maximal excitation wavelength at 542 nm and collected between 560 and 650 nm. For the selectivity study, different metal ions or bioactive small molecules: rat liver microsomes (active or inactive, 100  $\mu$ g/mL), Na<sup>+</sup> (10 mM), K<sup>+</sup> (10 mM), RNase A (10 ng/ $\mu$ L), RNase H (1 U/mL), GSH (10 mM) were added to the reaction buffer and reacted with TAH (100 nM) for 6 h at 37°C. The fluorescence emission intensity of each sample was measured.

### 1.6 <sup>1</sup>O<sub>2</sub> Production of TAH@TMPyP4 in Buffer Solution

A commercial reagent (1, 3-Diphenylisobenzofuran, DPBF) was chose to evaluate the generation of <sup>1</sup>O<sub>2</sub> in buffer solution. The TMPyP4, TAH@TMPyP4 and UB-TAH@TMPyP4 were dissolved in PBS buffer containing 10  $\mu$ g/mL DBPF, separately. Then, the mixed solution was irradiated with 660 nm light (2.2 mW·cm<sup>-2</sup>) for different time periods. The results were recorded with a UV-vis spectrophotometer.

### 1.7 Probe Stability Investigation

TAH (1  $\mu\text{M}$ ) was incubated in fresh DMEM medium plus 10% FBS at 37°C for different time spans (0, 3, 6, 9, 12, 24 h). Then, 10  $\mu\text{L}$  of the sample was mixed with glycerin (2  $\mu\text{L}$ ) and stained with SYBR Gold. Electrophoresis was performed in  $1 \times \text{TBE}$  buffer at 100 V for 30 min. Finally, gels were imaged on a Bio-Rad molecular imager.

### 1.8 Confocal Fluorescence Imaging of TAH in Living Cells

Activatable hypoxia imaging in living cells: First, human breast adenocarcinoma (MCF-7) cells were seeded in confocal culture dishes ( $1 \times 10^5$  cells per well) for 24 h and incubated with the TAH for 6 h under different  $\text{O}_2$  concentrations (21%, 10%, and 1%  $\text{O}_2$ ) and then washed three times with PBS buffer to remove the free TAH. Next, the TAH-incubated cells were subjected for imaging using laser scanning confocal microscope.

Imaging of cell membrane surface glycoprotein MUC1: The Apt strand labeled with Cy5.5 was incubated with each of these three kinds of cells (including MCF-7 cells, HepG2 cells, NIH/3T3 cells) for 30 min and then imaged them with laser scanning confocal microscope.

Generation of activatable formula  $^1\text{O}_2$ : First, MCF-7 cells were seeded in culture dishes and then placed in a cell incubator for 24 h. The cells were incubated with TAH@TMPyP4 at different  $\text{O}_2$  concentrations for 4 h then incubated with 2',7'-Dichlorofluorescein diacetate (DCFH-DA, 10  $\mu\text{M}$ ) in DMEM solution for 30 min, following by washing with PBS three times. For the cells that require light irradiation, 660 nm light at a density of  $2.2 \text{ mW} \cdot \text{cm}^{-2}$  was applied for 30 min. Fluorescence images of MCF-7 cells were immediately recorded using laser scanning confocal microscope.

### 1.9 Cytotoxicity Investigation

Cell viability was tested *via* 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Specifically, MCF-7 cells were seeded into 96-well plates for

48 h. Then, the cells were treated with TAH@TMPyP4 under different O<sub>2</sub> concentrations for 4 h following by irradiation with 660 nm light at 2.2 mW·cm<sup>-2</sup> for 30 min. After incubation for another 24 h, the cells were washed with PBS three times and 100 μL of MTT solution (0.5 mg/mL) was added to incubate together for 4 h. The supernatant was removed and 100 μL of dimethyl sulfoxide (DMSO) was then added to dissolve the formazan. The absorbance (490 nm) of the resulting solution was recorded using a microplate reader.

### 1.10 *In Vivo* Fluorescence Imaging

All animal operations were performed according to the protocol No. SYXK (Xiang) 2015-0017, and met the requirements with animal use and care regulations. 4T1 cells were injected into the subcutaneous tissue on the right side of the back of 4-week-old female nude mice to establish a tumor-bearing mouse model. When the tumors of the mice grew to around 6 mm, we performed live imaging of the mice. The tumor-bearing mice were divided into three groups: PBS group, UB-TAH group and TAH group. Three groups of mice were injected with PBS, 1 μM UB-TAH and 1 μM TAH in the tumor area and non-tumor area, respectively. The mice were anesthetized by air anesthesia, and then the mice were imaged by fluorescence using an intravital imaging system.

### 1.11 *In Vivo* Photodynamic Therapy Research

The MCF-7 tumor-bearing mouse model was established by injecting MCF-7 cells into the subcutaneous tissue of the right back of female nude mice. When the tumor volume reached approximately 60 mm<sup>3</sup>, the mice were randomly divided into four groups of four mice each. Mice were injected with PBS, TAH, and TAH@TMPyP4 every other day at a dose of 1 μM TMPyP4. The tumor volume and body weight of each mouse were measured every 2 days and monitored continuously for 15 days.

## 2. Experimental Data

Name	Sequence (5'-3')
<b>S1</b>	5'-TAT CAC CAG GCA GTT GAC AGT GTA GCA AGC TGT AAT AGA TGC GAG GGT CCA ATA CTT-3'
<b>S2</b>	5'-TCA ACT GCC TGG TGA TAA AAC GAC ACT ACG TGG GAA TCT ACT ATG GCG GCT CTT CTT-3'
<b>S3</b>	5'-TTC AGA CTT AGG AAT GTG CTT CCC ACG TAG TGT CGT TTG TAT TGG ACC CTC GCA TTT-3'
<b>S4</b>	5'-GAG CCC AGG TTC TCT TTTTTT ACA TTC CTA AGT CTG AAA CAT TAC AGC TTG CTA CAC GAG AAG AGC CGC CAT AGT A-3'
<b>L1</b>	5'- <u>GGT GGT GGT GGT TGT GGT GGT GGT GG</u> AGA GAA CCT GGG CTC TT AAA CTC TAA TTG TA CCA GGG TAT CC-3'
<b>L2</b>	5'-TAMRA- TA CAA TTA GAG TTT AA-BHQ2-3'
<b>L2'</b>	5'-TAMRA- TA CAA TTA GAG TTT AA-3'
<b>Apt</b>	5'-GCA GTT GAT CCT TTG GAT ACC CTG G-Cy5.5-3'

**Table S1** Oligonucleotides used in this work. The underlined part indicates the G-tetramer fragment.

Name	Modification group	Purity value (%)
L2	5'TAMRA,3'BHQ2	99.07
L2'	5'TAMRA	99.09
Apt	3'Cy5.5	96.71

**Table S2** HPLC purity values of fluorophore-labeled strands used in this work.

These data are provided by Sangon Bioengineering Co., Ltd (Shanghai, China).

## HPLC spectrum of L2 strand:


Empower<sup>®</sup> 3  
SOFTWARE

GB138

## 样品信息

样品名称:	1931672647	采集者:	System
样品类型:	未知	样品组名称:	230411
瓶号:	1	采集方法组:	GB15
进样次数:	1	处理方法:	gb14
进样体积:	70.00 ul	通道名称:	W2489 ChA
运行时间:	16.0 Minutes	处理通道注释:	W2489 ChA 260nm
采集时间:	2023/4/17 20:46:44 CST		
处理时间:	2023/4/18 11:52:34 CST		

## 自动标尺色谱图



名称	保留时间 (分钟)	峰结果		
		面积 (微伏*秒)	高度 (微伏)	% 面积
1	9.533	28055	3020	0.25
2	9.767	22188	9159	0.20
3	9.918	11082541	974193	99.07
4	10.267	53726	8814	0.48

报告用户: System  
 报告方法: GB138  
 报告方法 ID: 1377  
 页码: 1 (共计 1)

项目名称: HPLC检测1  
 打印日期:  
 2023/4/18  
 11:52:50 PRC



## HPLC spectrum of L2' strand:


Empower<sup>®</sup> 3  
SOFTWARE

GB15

## 样品信息

样品名称:	1931672648	采集者:	System
样品类型:	未知	样品组名称:	230411
瓶号:	2	采集方法组:	GB
进样次数:	1	处理方法:	gb14
进样体积:	70.00 ul	通道名称:	W2489 ChA
运行时间:	16.0 Minutes	处理通道注释:	W2489 ChA 260nm
采集时间:	2023/4/17 21:37:03 CST		
处理时间:	2023/4/18 11:57:14 CST		

## 自动标尺色谱图



峰结果				
名称	保留时间 (分钟)	面积 (微伏*秒)	高度 (微伏)	% 面积
1	10.629	19251	2901	0.19
2	11.133	29305	13150	0.29
3	11.258	9962977	1384021	99.09
4	11.483	43273	7573	0.43

报告用户: System  
 报告方法: GB15  
 报告方法 ID: 1378  
 页码: 1 (共计 1)

项目名称: HPLC检测1  
 打印日期:  
 2023/4/18  
 11:57:30 PRC


## HPLC spectrum of Apt strand:

Empower<sup>3</sup>  
SOFTWARE

GB15

样品信息			
样品名称:	1932201337	采集者:	System
样品类型:	未知	样品组名称:	230411
瓶号:	3	采集方法组:	GB
进样次数:	1	处理方法:	GB15
进样体积:	70.00 uL	通道名称:	W2189 ChA
运行时间:	16.0 Minutes	处理通道注释:	W2189 ChA 260nm
采集时间:	2023/4/17 21:54:11 CST		
处理时间:	2023/4/18 11:58:43 CST		

自动标尺色谱图




峰结果				
名称	保留时间 (分钟)	面积 (微伏*秒)	高度 (微伏)	% 面积
1	13.990	297347	54468	2.79
2	14.120	10314461	1873717	96.71
3	14.267	53782	13070	0.50

报告用户: System  
 报告方法: GB15  
 报告方法 ID: 1378  
 页码: 1 (共计 1)


项目名称: HPLC检测1  
 打印日期:  
 2023/4/18  
 11:58:54 PRC

These HPLC spectrograms are provided by Sangon Bioengineering Co., Ltd (Shanghai, China).




**Fig. S1** Schematic diagrams of the assembly of TAH (A), UB-TAH (B), TAH@TMPyP4(C).


**Fig. S2** 1.5% agarose gel electrophoresis showed self-assembly of TDN (at a concentration of 1  $\mu$ M). Lane 1: S1; Lane 2: S1 + S2; Lane 3: S1 + S2 + S3; Lane 4: S1 + S2 + S3 + S4. Stained with SYBR Gold.




**Fig. S3** (A) Fluorescence emission spectra of TMPyP4 (1 μM) upon addition of different concentrations (0, 10, 25, 50, 75, 100 nM and 125 nM) of L1,  $\lambda_{ex} = 435$  nm. (B) Fluorescence quantitative curve of TMPyP4 with addition of L1.  $\lambda_{em} = 668$  nm.




**Fig. S4** Standard curve of fluorescence intensity of TMPyP4 (0.1-0.7 μM).  $\lambda_{ex} = 435$  nm,  $\lambda_{em} = 668$  nm. Error bars represent standard deviations from three repeated experiments.




**Fig. S5** UV-vis absorption spectra of mixed solutions containing TMPyP4 and DPBF irradiated for different time. The concentration of DPBF is 10  $\mu\text{g/mL}$ .




**Fig. S6** UV-vis absorption spectra of mixed solutions containing TDN@TMPyP4 and DPBF irradiated for different time. The concentration of DPBF is 10  $\mu\text{g/mL}$ .




**Fig. S7** UV-vis absorption spectra of mixed solutions containing UB-TDN@TMPyP4 and DPBF irradiated for different time. The concentration of DPBF is 10  $\mu\text{g}/\text{mL}$ .




**Fig. S8** Normalized intensity of UV-vis absorption of DPBF in different mixed solutions irradiated for different time. Error bars represent standard deviations from three repeated experiments.



**Fig. S9** Fluorescence emission intensity changes of 100 nM TAH in the presence of different proteins: MUC1 (active or inactive, 100 nM), GOX (100  $\mu$ M), RNase H (1 U/mL), RNase A (10 ng/ $\mu$ L), APE1 (1 U/mL) ( $F/F_0$ ,  $F$  and  $F_0$  represent the Cy5.5 fluorescence emission intensity of TAH nanoprobe before and after adding MUC1 or other substances, respectively).  $\lambda_{ex}$  = 673 nm,  $\lambda_{em}$  = 710 nm. Error bars represent standard deviations from three repeated experiments.




**Fig. S10** Fluorescence emission spectrum of TAH upon incubation with different concentrations (0, 25, 50, 100, 125, 150, 175, 200  $\mu$ g/mL) of inactivated liver microsomes and NADPH (50  $\mu$ M) under 1% O<sub>2</sub> concentration.  $\lambda_{ex}$  = 542 nm.



**Fig. S11** Fluorescence emission spectra of TAH upon incubated with liver microsomes (100  $\mu\text{g/mL}$ ) and NADPH (50  $\mu\text{M}$ ) at 1%  $\text{O}_2$  for different time. Inset: The TAMRA fluorescence enhancement of TAH after incubated with liver microsomes (100  $\mu\text{g/mL}$ ) and NADPH (50  $\mu\text{M}$ ) at 1%  $\text{O}_2$  for different time ( $F/F_0$ ,  $F$  and  $F_0$  represent the fluorescence intensity of TAMRA before and after incubation of TAH with liver microsomes and NADPH for different time).  $\lambda_{\text{ex}} = 542 \text{ nm}$ ,  $\lambda_{\text{em}} = 580 \text{ nm}$ . Error bars represent standard deviations from three repeated experiments.


**Fig. S12** Electropherograms of TAH which were incubated in fresh medium containing 10% fetal bovine serum for different time. Stained with SYBR Gold. The concentration of TAH is 1  $\mu\text{M}$ .






**Fig. S13** Fluorescence emission intensity changes of 100 nM TAH in the presence of different metal ions or bioactive small molecules: rat liver microsomes (active or inactive, 100  $\mu\text{g}/\text{mL}$ ),  $\text{Na}^+$  (10 mM),  $\text{K}^+$  (10 mM), RNase A (10  $\text{ng}/\mu\text{L}$ ), RNase H (1 U/mL), GSH (10 mM) ( $F/F_0$ ,  $F$  and  $F_0$  represent the TAMRA fluorescence emission intensity of TAH nanoprobe before and after adding rat liver microsomes or other interfering substances, respectively).  $\lambda_{\text{ex}} = 542 \text{ nm}$ ,  $\lambda_{\text{em}} = 580 \text{ nm}$ . Error bars represent standard deviations from three repeated experiments.

**Fig. S14** Confocal fluorescence images of MCF-7, HepG2 and NIH/3T3 cells upon incubated with Apt strand labeled by Cy5.5 at 21%  $\text{O}_2$ . Scale bar: 20  $\mu\text{m}$ .  $\lambda_{\text{ex}} = 640 \text{ nm}$ .




**Fig. S15** Confocal fluorescence images of MCF-7 cells incubated with membrane dye (Dil) and TAH respectively. Scale bar: 20  $\mu\text{m}$ .  $\lambda_{\text{ex}} = 561 \text{ nm}$ .




**Fig. S16** (A) Confocal fluorescence images of MCF-7 cells upon incubated with TAH under different O<sub>2</sub> concentrations (21%, 10%, and 1% O<sub>2</sub>). Scale bar: 20  $\mu\text{m}$ . (B) The relative mean fluorescence intensities of TAMRA under different conditions.  $\lambda_{\text{ex}} = 561 \text{ nm}$ . Error bars represent standard deviations from three repeated experiments.


**Fig. S17** Confocal fluorescence images of MCF-7 cells upon incubated with TAH at different O<sub>2</sub> concentrations (21%, 10%, and 1% O<sub>2</sub>). Scale bar: 50  $\mu$ m. TAMRA channel:  $\lambda_{\text{ex}} = 561$  nm, Cy5.5 channel:  $\lambda_{\text{ex}} = 640$  nm.




**Fig. S18** The relative mean fluorescence intensities of Cy5.5 and TAMRA collected from different cells (MCF-7 cells, HepG2 cells, and NIH/3T3 cells) in Fig. 3B.




**Fig. S19** Confocal fluorescence images of THA@TMPyP4 pre-treated MCF-7 cells at different O<sub>2</sub> concentrations (21% O<sub>2</sub>, 10% O<sub>2</sub> and 1% O<sub>2</sub>) followed by illumination and DCFH-DA treatment. The cells without any treatment were set as the control group. Scale bar: 20  $\mu$ m.  $\lambda_{ex}$  = 488 nm.



**Fig. S20** Fluorescence quantification of DCF collected from the MCF-7 cells upon incubated with THA@TMPyP4 and DCFH-DA probes at different O<sub>2</sub> concentrations (21%, 10% and 1% O<sub>2</sub>).  $\lambda_{ex}$  = 488 nm. Error bars represent standard deviations from three repeated experiments.



**Fig. S21** Confocal fluorescence imaging images of pyridium iodide stained MCF-7 cells which treated with different conditions (a: Control, b: TAH@TMPyP4, c: TAH@TMPyP4 under 1% O<sub>2</sub>). Scale bar: 20  $\mu$ m.  $\lambda_{ex}$  = 561 nm.



**Fig. S22** (A) Schematic diagram of *in vivo* fluorescence imaging of mice injected with PBS (a), UB-TAH (b) and TAH (c) into normal and tumor sites, respectively. Circle I is the normal area, and circle II is the tumor area. (B) *In vivo* fluorescence imaging of mice after injection of TAH into the tumor area over time. (C) Quantitative fluorescence analysis of Fig. S22B.

**Fig. S23** Levels of urea (a marker of renal function) (A),<sup>B</sup> alanine aminotransferase (GPT, a marker of liver function) (B) and lactate dehydrogenase (LDH, a marker of lung function) (C) in serum of mice after different treatments. The different treatment groups are consistent with Figure 4B.